Goldfinch Bio
We aspire to save kidneys and end dialysis by delivering disease-modifying precision medicines for patients.
📍 Cambridge, Massachusetts
Stats
- Employees (LinkedIn)
- 4
- Size bucket
- 11-50 employees
- Followers
- 3782
- Founded
- 2016
- Org type
- Privately Held
- Country
- US
- LinkedIn ID
- 10997223
- Slug
- goldfinch-bio
Industries
Specialties
About
With our sole focus on kidney diseases, we aspire to be the world’s leading precision medicine kidney company. There are few therapeutic options that target the underlying cause of disease. Our solution to address this growing need is applying precision medicine to pioneer the discovery, development and commercialization of kidney disease treatments. Historically, there has been a ‘one size fits all’ approach to treating kidney disease. This has been due to the lack of understanding of kidney disease at the molecular level. Thanks to a growing understanding of kidney biology and genetics, including pioneering research by the founders of Goldfinch, the scientific community is starting to understand the heterogeneity inherent in kidney diseases. Our precision medicine product engine is the foundation of our approach. Our product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse patient populations to identify patient subsets most likely to respond to our treatment. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet medical need. If embracing creativity and candor, thriving on challenges, and empowering your teammates to succeed excites and inspires you, join us as we champion hope and change the face of kidney disease.
Locations (1)
- 215 First Street, Suite 400, Cambridge, Massachusetts 02142, US